Despite its growing popularity, the clinical efficacy and safety of BPC-157 remain unproven, raising significant ethical and legal concerns
CENTRALLY-ACTING ANTI-OBESITY DRUGS Monoamine Neurotransmitter Modulators With the exception of the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide, currently available weight loss medications act on the central nervous system to enhance dopamine, norepinephrine, and serotonin action to enhance satiety, diminish hunger, and consequently affect weight loss
While some patients tolerate products well when appropriately selected, safety depends on skin sensitivity, product formulation, current routine, and clinical judgment
For both peptides, the primary safety concern is source quality, not the molecules themselves
Falling is a risk factor for bone fractures among men and women 60 years of age and older
For weight management, NICE has appraised several licensed medicines that are available through NHS pathways or regulated private clinics: Semaglutide (Wegovy) NICE Technology Appraisal TA875 recommends semaglutide as an option for managing overweight and obesity in adults with a BMI of 35 kg/m or more (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service
